Skip to main content
HIND
NASDAQ Life Sciences

Vyome Q3 Loss Narrows to $930K; Material Weaknesses Persist, FDA Seeks More VT-1953 Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.63
Mkt Cap
$11.44M
52W Low
$1.529
52W High
$5.88
52W Position info
6.6% above low
Off High info
72% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

HIND is trading near its 52-week low of $1.529 (6.6% above the low).

Summary

Vyome's Q3 loss narrowed to $930,325 from $8,595,300 and cash rose to $6.96 million, but material weaknesses remain unremediated, the going-concern language persists, and the FDA requested more data on the VT-1953 orphan drug application.


Key Events · Earnings and Guidance · HIND

  • Q3 Loss Narrows Sharply

    Net loss was $930,325 for the three months ended September 30, 2026 versus $8,595,300 a year earlier; the prior year included $7,705,533 of transactional fees.

  • Cash Rises on ATM Sales

    Cash and cash equivalents reached $6,956,822 at September 30, 2026 from $4,982,333 at December 31, 2025, after $5,285,868 of net proceeds from ATM share sales.

  • Material Weaknesses Unremediated

    Management concluded disclosure controls were not effective as of September 30, 2026 due to material weaknesses in policies and procedures, segregation of duties and technical accounting expertise; a new CFO was appointed September 1, 2026 to help remediate.

  • Going Concern and Runway

    The company states existing cash funds operating requirements for at least 15 months, including initiation of the VT-1953 pivotal trial, but not completion of the trial or other programs.


Analysis · HIND · Life Sciences

Vyome's quarterly loss shrank sharply to $930,325 from $8,595,300 a year ago, largely because last year carried $7.7 million of one-time merger transactional fees, while cash rose to $6.96 million on $5.29 million of ATM proceeds. Against that, the company still carries unremediated material weaknesses in internal control over financial reporting and a going-concern discussion: management says cash funds at least 15 months of operations but not the full VT-1953 pivotal trial, so another raise is likely. The FDA also asked for more information on the VT-1953 Orphan Drug Designation application in Q3, adding regulatory uncertainty to the lead program.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HIND was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $1.53 to $5.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HIND - Latest Insights

HIND
Nov 12, 2026, 6:33 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.63 info
Change: $0 (0%) info
Market Cap: $11.44M info
HIND
Oct 05, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $1.90
Real-time Price: $1.63 info
Change: -$0.270 (-14%) info
Market Cap: $11.44M info
HIND
Aug 25, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.25
Real-time Price: $1.63 info
Change: -$0.620 (-28%) info
Market Cap: $11.44M info
HIND
Aug 12, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.22
Real-time Price: $1.63 info
Change: -$0.590 (-27%) info
Market Cap: $11.44M info
HIND
May 29, 2026, 8:42 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.63 info
Change: -$0.670 (-29%) info
Market Cap: $11.44M info